骨盆淋巴管平滑肌瘤用癌伏妥治療成功:病例報告
吳宗憲、Sharjil Wahid、江博暉
高雄長庚醫院泌尿科
Pelvic Lymphangioleiomyomatosis treated successfully with everolimus: Case report
Tsung Hsien Wu, Sharjil Wahid, Po Hui Chiang
 
Purpose: Lymphangioleiomyomatosis (LAM) is a rare disease affecting young women caused by abnormal proliferation of smooth muscle-like cells (LAM cells) in the lungs and extrapulmonary sites (extrapulmonary LAM). The objective of this case series is to demonstrate marked regression in 3 cases of retroperitoneal LAM after treatment with everolimus, an mTOR inhibitor.
Materials and Methods: We enrolled 3 cases with large volume, extrapulmonary pelvic LAM, and evaluated them with contrast-enhanced abdominal Computed Tomographic (CT) scans at presentation and serially during treatment with everolimus. Results were objectively quantified using the Response Evaluation Criteria in Solid Tumors, RECIST, Version 1.1.
Results: After 6-18 months of treatment with everolimus, all 3 patients showed substantial reduction in the volume of their tumors. The first had about 50% regression of the pelvic LAM and renal angiomyolipoma(AML). The second patient had extensive abdomino-pelvic LAM which after treatment showed complete remission. Both patients have not demonstrated disease progression after nearly 4 and 2 years of follow up, respectively.
Conclusions: This case series demonstrates the enormous value of mTOR inhibitors (specifically everolimus) in the management of extrapulmonary pelvic LAM, of which there is no effective treatment currently available.
 
    位置
    資料夾名稱
    摘要
    發表人
    TUA秘書處
    單位
    台灣泌尿科醫學會
    建立
    2017-06-01 11:15:28
    最近修訂
    2017-06-01 11:21:09
    更多